DNA Script announced a €42.4 million extension to its Series B financing led by Casdin Capital.
DNA Script, a Paris, France-based DNA engineering company, announced an extension of €42.4 million ($50M) to its Series B financing.
The round was led by Casdin Capital and included funding from Danaher Life Sciences, Agilent Technologies, Merck KgaA, Darmstadt, Germany, through its corporate venture arm, M Ventures – three of the world’s leaders in oligo synthesis – LSP, the Bpifrance Large Venture Fund and Illumina Ventures.
Including this money, the total investment of this round is around €75.5 million.
DNA Script, founded in 2014 and led by CEO Thomas Ybert, is working on revolutionizing DNA write with enzymes, in order to accelerate breakthroughs in personalised human health and the life sciences. Their flagship and first product is a world-first DNA printer, which can be used in many industries and applications, including developing new drugs and tests for cancer, as well as new foods like artificial meat.
The funds raised will be put towards a second project, which also received around €19.5 million from Intelligence Advanced Research Projects Activity’s Molecular Information Storage programme. This project aims to develop deployable DNA data storage and retrieval technology as part of the Molecular Encoding Consortium, along with partners at the Broad Institute and Harvard University.